Employer health cost crunch is worse than projected

There's new evidence that double-digit health cost increases were hitting employers well before the forecasts of big spikes for 2027 — forcing big changes in workplace coverage for millions of Americans. Why it matters: The findings offer a higher-resolution view of how much health spending is putting a drag on the labor market and increasing affordability concerns for the approximately 160 million Americans who get coverage through work. They also show how factors like surprise billing disputes, more cancer diagnoses and expensive specialty drugs are combining to exert cost pressure, with no immediate relief in sight. Driving the news: A new Gallagher benefits survey of more than 3,700 firms found 36% of the companies reported premium increases of 10% or more during their most recent renewal. Pharmacy costs account for a quarter or more of some companies' total health spending. Cancer care is the No. 1 cost driver for about 7 in 10 firms. The survey, fielded from January to March, also found employers are trying to avoid saddling workers with a disproportionate share of rising costs while struggling to balance the quality of care with their financial risk. "The last two renewal cycles have been unlike anything we've ever seen before," said Robby White, Gallagher's U.S. benefits business line leader. "It's unsustainable, obviously. Every additional dollar that an employer spends on health care, they can't spend on their employees." Between the lines: The 2027 coverage year was already shaping up to be painful for many employers. Projections are showing premium spikes due to rising demand for health services, more chronic disease and increased use of drugs like GLP-1s. In fact, double-digit premium increases for both the 2026 and 2027 plan years suggest there are more underlying causes, according to benefits experts. One leading factor is chronic disease: More people are being diagnosed with cancer at a younger age, and advanced treatments and related care can result
Read the full story at Axios →